Rome V Bowel Disorders: Gastroenterology | May 2026

The Rome V Bowel Disorders chapter is one of the most clinically relevant revisions in Rome V because it substantially updates the diagnostic framework for disorders of gut–brain interaction (DGBI) involving bowel symptoms. The major conceptual advance is a shift away from exclusion-based diagnosis and rigid “functional” terminology toward positive symptom-based diagnosis, biologically plausible phenotyping, and pragmatic treatment pathways. Rome V also reframes bowel disorders as a spectrum of overlapping DGBI, rather than isolated, mutually exclusive syndromes.

1. “Functional Bowel Disorders” Are Now Renamed “Bowel Disorders”

A major Rome V conceptual change is the abandonment of the term functional bowel disorders in favor of bowel disorders (BDs). This aligns with the broader Rome V movement away from the term “functional,” which has long been criticized as mechanistically vague, scientifically outdated, and often stigmatizing for patients.

This change reflects a modern DGBI framework:

symptoms are biologically real,

mechanisms are multifactorial,

and absence of structural disease does not imply absence of pathophysiology.

2. Rome V Reclassifies Bowel Disorders Into 6 Distinct Categories

Rome V now classifies bowel disorders into 6 categories:

Irritable bowel syndrome (IBS)

Chronic constipation (CC)

Functional diarrhea (FDr)

Functional abdominal bloating (FAB)

Unclassified bowel disorder (U-BD)

Opioid-induced constipation (OIC)

This classification is important because it better reflects clinical overlap and real-world symptom clusters. The spectrum diagram on page 2 (Figure 1) is particularly useful because it visually demonstrates how constipation, diarrhea, pain/discomfort, bloating, and distension overlap across syndromes rather than existing as isolated entities.

3. IBS Criteria Have Been Broadened: “Discomfort” Is Reintroduced

This is one of the most important Rome V changes.

Rome V reintroduces “abdominal discomfort” into the diagnostic criteria for IBS, reversing one of the most debated Rome IV decisions.

Under Rome IV, IBS required abdominal pain at least 1 day/week. Rome V now defines IBS by:

recurrent, but not continuous, abdominal pain and/or discomfort

at least 3 days/month

for the last 3 months,

with symptom onset ≥6 months before diagnosis,

associated with ≥2 stool-related features.

This is a major and clinically sensible revision because:

many true IBS patients report discomfort rather than pain,

symptom language varies across cultures,

and Rome IV likely underdiagnosed IBS by being too restrictive.

4. Rome V Lowers the IBS Symptom Frequency Threshold

Rome V lowers the IBS frequency threshold from ≥1 day/week (Rome IV) to ≥3 days/month.

This is a highly practical and evidence-based change.

The Rome Foundation Global Epidemiology Study showed that Rome IV significantly reduced IBS prevalence largely because the pain threshold was too stringent. Rome V corrects this by lowering the threshold and restoring diagnostic sensitivity without abandoning specificity.

5. IBS Pain Must Be “Recurrent, Not Continuous”

Rome V now explicitly states that IBS symptoms should be recurrent, not continuous.

This is an important refinement because it helps distinguish IBS from centrally mediated abdominal pain syndrome, where pain is more continuous and less clearly linked to bowel function.

This is a subtle but clinically useful diagnostic discriminator.

6. IBS Is Explicitly a Positive Diagnosis—Not a Diagnosis of Exclusion

Rome V strongly reinforces one of the most important modern DGBI principles:

IBS should be diagnosed positively based on symptoms, not by exclusion.

This is a major practice message.

When Rome V criteria are met and alarm features are absent:

diagnostic confidence should be high,

testing should be selective,

and clinicians should avoid reflex over-investigation.

Rome V strongly discourages exhaustive exclusionary workups in routine IBS.

7. Diagnostic Testing in IBS Should Be Selective and Targeted

Rome V recommends limited, targeted testing in suspected IBS rather than broad exclusionary panels.

Most clinically relevant recommendations:

Fecal calprotectin is useful to exclude IBD (high negative predictive value)

Celiac serology should be considered, especially in IBS-D

stool infection testing only when epidemiologically indicated

colonoscopy only when alarm features exist or microscopic colitis is suspected

routine stool microbiome/SIBO testing is not recommended.

The stepwise diagnostic algorithm on page 7 (Figure 4) is one of the most clinically useful figures in the chapter because it operationalizes efficient diagnostic triage.

8. Rome V Does Not Recommend Routine SIBO Testing in IBS

This is one of the most important practical updates.

Rome V explicitly states that routine breath testing for SIBO (or intestinal methanogen overgrowth) is not recommended in the initial diagnostic evaluation of IBS.

The rationale is strong:

poor test standardization,

limited diagnostic accuracy,

inconsistent clinical utility,

insufficient evidence that testing improves outcomes.

This is an important de-escalation in an overused area of practice.

9. Bile Acid Malabsorption Is Repositioned as a Selective Secondary Consideration

Rome V does not recommend routine initial testing for bile acid malabsorption (BAM) in IBS-D, but advises considering it in:

chronic diarrhea,

refractory IBS-D,

post-cholecystectomy patients,

or when standard therapy fails.

This is a practical and evidence-aligned change that appropriately narrows BAM testing.

10. Chronic Constipation Replaces “Functional Constipation”

Rome V replaces functional constipation (FC) with chronic constipation (CC).

This is both a linguistic and conceptual update:

more clinically intuitive,

less stigmatizing,

and more consistent with contemporary DGBI terminology.

Rome V also explicitly notes that:

CC, FC, and CIC are largely interchangeable in practice,

but CC is now preferred nomenclature.

11. The Main Distinction Between IBS-C and CC Is Predominant Pain

Rome V clarifies that the key clinical distinction between IBS-C and CC is not constipation severity—it is whether abdominal pain/discomfort is the predominant symptom.

This is one of the most clinically useful practical clarifications in the chapter.

IBS-C = constipation + predominant abdominal pain/discomfort

CC = constipation with minimal/non-predominant pain

12. Rome V Delays Anorectal and Transit Testing in Chronic Constipation

Rome V recommends that anorectal physiology and transit testing should not be part of the initial routine evaluation in most patients with chronic constipation.

Instead:

begin with symptom-based diagnosis,

initiate empiric therapy,

reserve anorectal testing for refractory symptoms or suspected defecatory disorder.

This is a major practical simplification.

13. Functional Diarrhea Is Preserved but More Clearly Distinguished From IBS-D

Rome V retains functional diarrhea (FDr) and clarifies that it differs from IBS-D because abdominal pain is not the predominant symptom.

This distinction mirrors the IBS-C vs CC separation and improves internal diagnostic consistency across bowel disorders.

14. Functional Abdominal Bloating Is Now a Formal Standalone Disorder

Rome V formally recognizes functional abdominal bloating (FAB) as a distinct bowel disorder rather than merely a secondary symptom construct.

This is an important upgrade because bloating/distension is:

highly prevalent,

often the dominant symptom,

and frequently underrecognized in routine practice.

Rome V also formally distinguishes:

bloating = subjective sensation

distension = objective measurable increase in girth

15. Abdominophrenic Dyssynergia Is Highlighted as a Key Mechanism of Bloating

One of the most important mechanistic additions in Rome V is the recognition of abdominophrenic dyssynergia as a major pathophysiologic driver of visible abdominal distension.

This is a highly important mechanistic update.

Rome V emphasizes that many patients with bloating do not have excess intestinal gas. Instead, visible distension may result from:

paradoxical diaphragmatic contraction,

abdominal wall relaxation,

and altered viscerosomatic reflexes.

This is one of the most important physiologic advances in the chapter.

16. Rome V Formalizes a Stepwise, Multidisciplinary Treatment Pyramid

The treatment pyramid on page 7 (Figure 5) is one of the most practical additions in Rome V. It formalizes a stepwise approach to bowel disorders:

diagnosis and explanation

reassurance and symptom framing

dietary intervention

symptom-targeted pharmacotherapy

brain–gut behavioral therapies

multidisciplinary care

This figure is one of the most clinically useful Rome V additions because it operationalizes modern DGBI care.

17. Rome V Strongly Emphasizes Brain–Gut Behavioral Therapies

Rome V gives stronger support than prior iterations to:

CBT,

gut-directed hypnotherapy,

mindfulness,

digital behavioral therapies.

This is a major management evolution and reinforces DGBI as a gut–brain disorder rather than a purely bowel-localized condition.

Clinical Bottom Line

The Rome V Bowel Disorders chapter modernizes bowel DGBI by replacing rigid exclusionary frameworks with positive diagnosis, selective testing, symptom phenotyping, and multidisciplinary care.

The most practice-changing updates are:

“functional bowel disorders” renamed bowel disorders

IBS now includes pain and/or discomfort

IBS threshold lowered to ≥3 days/month

IBS must be recurrent, not continuous

IBS is a positive diagnosis, not exclusionary

routine SIBO testing is discouraged

CC replaces functional constipation

IBS-C vs CC distinction is based on predominant pain

FAB is now a formal standalone disorder

abdominophrenic dyssynergia is recognized as a key bloating mechanism

care is formalized through a stepwise multidisciplinary treatment pyramid.